GNI Group Ltd 2160.T-JP:Tokyo Stock Exchange

*Data is delayed | JPY
Last | 1:17 PM JST
1,989.00quote price arrow down-23.00 (-1.14%)
Volume
554,500
52 week range
1,171.00 - 4,070.00

...

Loading . . .
  • Open1,990.00
  • Day High2,010.00
  • Day Low1,965.00
  • Prev Close2,012.00
  • 52 Week High4,070.00
  • 52 Week High Date10/06/20
  • 52 Week Low1,171.00
  • 52 Week Low Date04/22/20

Key Stats

  • Market Cap819.74M
  • Shares Out43.51M
  • 10 Day Average Volume540,260
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change10.01

KEY STATS

  • Open1,990.00
  • Day High2,010.00
  • Day Low1,965.00
  • Prev Close2,012.00
  • 52 Week High4,070.00
  • 52 Week High Date10/06/20
  • 52 Week Low1,171.00
  • 52 Week Low Date04/22/20
  • Market Cap819.74M
  • Shares Out43.51M
  • 10 Day Average Volume540,260
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change10.01

RATIOS/PROFITABILITY

  • EPS (TTM)17.00
  • P/E (TTM)117.00
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From GNI Group Ltd

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
GNI Group Ltd. is a Japan-based company engaged in new drug production activities utilizing biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. It is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for...
Ying Luo
Chief Executive Officer
Thomas Eastling
Chief Financial Officer
Address
3F, Nihonbashi-Honcho YS Bldg
2-2-2, Nihonbashi Hon-cho
Chuo-ku, TKY
103-0023
Japan